New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options

Anne S. Tsao, Harvey I. Pass, Andreas Rimner, Aaron S. Mansfield

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations

Abstract

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device approved for use with platinum-pemetrexed, and also for immunotherapy agents to be included as a frontline treatment option in unresectable disease. Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly identify the MPM histology to determine an optimal treatment plan. Patients with nonepithelioid MPM may have a greater magnitude of benefit to dual immunotherapy checkpoint inhibitors and this regimen should be preferred in the frontline setting for these patients. However, all patients with MPM can derive benefit from immunotherapy treatments, and these agents should ultimately be used at some point during their treatment journey. There are ongoing studies in the frontline unresectable setting that may further define the frontline therapy space, but a critical area of research will need to focus on the immunotherapy refractory population. This review article will describe the new developments in the areas of biology with genomics and chromothripsis, and also focus on updates in treatment strategies in radiology, surgery, radiation, and medical oncology with cellular therapies. These recent innovations are generating momentum to find better therapies for this disease.

Original languageEnglish (US)
Pages (from-to)681-692
Number of pages12
JournalJournal of Clinical Oncology
Volume40
Issue number6
DOIs
StatePublished - Feb 20 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options'. Together they form a unique fingerprint.

Cite this